Gelmedix
GelMEDIX develops regenerative medicine solutions focused on combating vision loss through a proprietary biomaterials platform. The company's lead program centers on iPSC-derived Retinal Pigment Epithelial (RPE) cell therapy delivered via an advanced hydrogel scaffold. This approach aims to regenerate lost retina structures to preserve vision for patients suffering from Geographic Atrophy.
- Biotechnology
Funding
Raised to date
$16.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Reza Dana
Unknown
Product
Problem
Current treatments for complex ophthalmic conditions often suffer from inconsistent drug absorption and limited localized efficacy, hindering cell viability and tissue regeneration. This can lead to suboptimal outcomes in restoring vision.
Solution
Gelmedix is developing a biomaterial platform designed to enhance the targeted delivery of therapeutics for ocular cell therapy. Their engineered formulations aim to improve cell viability, engraftment, and tissue regeneration within the eye. By optimizing these factors, Gelmedix seeks to improve the effectiveness of treatments for various ophthalmic conditions and ultimately restore vision. The platform focuses on addressing the limitations of current approaches to ocular cell therapy.
Target Audience
The primary target audience includes ophthalmologists and researchers focused on developing and administering advanced treatments for complex ophthalmic conditions.
Features
- Biomaterial formulations engineered to improve cell viability in ocular treatments.
- Enhanced engraftment of therapeutic cells within the eye.
- Promotion of tissue regeneration for improved visual outcomes.
- Targeted delivery of therapeutics to specific areas within the eye.